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a b s t r a c t
Here we deﬁne the epitopes on HA that are targeted by a group of 9 recombinant monoclonal antibodies
(rmAbs) isolated from memory B cells of mice, immunized by infection with A(H1N1)pdm09 virus
followed by a seasonal TIV boost. These rmAbs were all reactive against the HA1 region of HA, but
display 7 distinct binding footprints, targeting each of the 4 known antigenic sites. Although the rmAbs
were not broadly cross-reactive, a group showed subtype-speciﬁc cross-reactivity with the HA of A/
South Carolina/1/18. Screening these rmAbs with a panel of human A(H1N1)pdm09 virus isolates
indicated that naturally-occurring changes in HA could reduce rmAb binding, HI activity, and/or virus
neutralization activity by rmAb, without showing changes in recognition by polyclonal antiserum. In
some instances, virus neutralization was lost while both ELISA binding and HI activity were retained,
demonstrating a discordance between the two serological assays traditionally used to detect
antigenic drift.
Published by Elsevier Inc.
Introduction
Inﬂuenza viruses are common pathogens of many species,
including humans, in whom seasonal inﬂuenza epidemics are a
signiﬁcant cause of global disease with a high annual public health
and economic burden (Molinari et al., 2007). Vaccination is the
most effective public health counter-measure against inﬂuenza.
Antibodies play an important protective role against inﬂuenza
infections, and the goal of immunization against inﬂuenza viruses
is to induce a protective antibody response against the immuno-
dominant surface protein, hemagglutinin (HA). As a small number
of mutations in HA allow the virus to avoid neutralization by
antibodies, inﬂuenza viruses rapidly evolve resistance to popula-
tion immunity, so that inﬂuenza vaccines need to be reformulated
on a regular basis. In addition to the antigenic match between
vaccine and circulating virus, the protective efﬁcacy of inﬂuenza
vaccination can vary depending on the age, history of exposure
and health status of the vaccinee.
HA binds to the viral receptors, sialic acids (SA), on host cells
facilitating virus entry, and also brings about membrane fusion
between the virus and cellular membranes that is triggered by the
low pH of the endosomal compartment. Structurally, HA is
composed of a globular head that includes the receptor-binding
site (RBS) and previously deﬁned antigenic sites, and a stem region
that includes the membrane fusion peptide, as well as transmem-
brane and cytosolic regions. A number of lines of evidence,
including the generation of antibody escape mutants and mea-
surement of binding to speciﬁc mutants, have shown that protec-
tive antibodies tend to bind to speciﬁc antigenic sites on the
globular head (Wan et al., 2014; Rudneva et al., 2010). For the H1
subtype of HA, the sites are termed Sa, Sb, Ca1, Ca2, and Cb (Caton
et al., 1982; Yewdell and Gerhard 1981). The residues comprising
these antigenic sites tend to be highly variable over time and, since
mutations in these sites are well tolerated by viruses, this allows
mutant viruses to arise that are capable of infecting individuals
immune to the parent inﬂuenza strain. Protective antibodies can
also bind to regions outside of the deﬁned antigenic sites on the
HA head (Zhu et al., 2013; Matsuzaki et al., 2014). In many cases,
these regions of HA are more conserved than the antigenic sites,
and antibodies targeting these regions may provide cross-reactive
protection against multiple strains of inﬂuenza (Lee et al., 2014;
Whittle et al., 2011; Hong et al., 2013; Krause et al., 2011).
Immunity to inﬂuenza is assessed using serological assays, such
as hemagglutination inhibition (HI) or virus neutralization (VN)
assays, that are correlated with protection against disease(Tsang
et al., 2014; Hobson et al., 1972; Coudeville et al., 2010; Cox, 2013).
These assays measure the “average” speciﬁcities and afﬁnity of a
complex mixture of antibodies. In principle, sequence analysis of
the variable regions of antibodies in combination with their
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functional characteristics may provide more detailed information
on the predicted immune response, including identiﬁcation of
antibodies that are present below the limit of detection of
conventional assays but that have the potential for cross-
protective or broadly reactive immunity.
Antibodies are comprised of a heavy and light chain. The heavy
chain is the result of genomic recombination of a variable (IGHV),
diversity (IGHD), and a joining (IGHJ) gene, while the light chain is
composed of a variable (IGKV or IGLV) and joining (IGKJ) gene
recombination. In a previous study, we analyzed the diversity and
nature of the mouse antibody response against inﬂuenza HA by
cloning IgH and IgL chains from individual B cells (Wilson et al.,
2014). This work demonstrated that the antibody response targeting
the HA of A(H1N1)pdm09 (following this particular immunization
regimen) is relatively narrow, being dominated by approximately 100
heavy chain VDJ germline sequences and approximately 35 light
chain VJ germline sequences. Here, we deﬁne the epitopes on HA
that are targeted by a group of nine representative recombinant
monoclonal antibodies (rmAbs) from this response and begin to
deﬁne antigen and genomic sequence information associated with
antibody recognition and neutralizing activity.
Results
rmAb recognize multiple epitopes on HA
In previous work we immunized mice by sub-lethal infection
with A(H1N1)pdm09 virus and boosted with TIV, leading to a
robust antibody response that predominately targeted the HA of
pdm09 viruses (Wilson et al., 2014). We used single-cell cloning
from memory B cells to identify a number of rmAbs, including nine
that bound H1N1pdm recHA with sub-nanomolar steady-state
afﬁnity (Wilson et al., 2014). These rmAb contain the most common
IgH VDJ and IgK VJ rearrangements identiﬁed in that screen, and
each displayed HI activity toward H1N1pdm virus (Wilson et al.,
2014). To determine the binding sites of these rmAbs, we generated
a panel of 20 recHAs, each containing a single point mutation
within or near the deﬁned antigenic regions of CA/07 (Fig. 1A and
B), and measured binding afﬁnity of the rmAbs to each by BLI.
Control monoclonal antibodies 26-D11 and Y2_50132_1C04 (“C04”)
bound with high afﬁnity to the wild-type HA, and as expected their
binding was reduced by mutations in antigenic site Sa (S121K) and
in the stalk region (I372K) respectively (Fig. 2B and data not shown).
For 6 of the 9 rmAbs, binding was compromised by mutation(s) in a
single antigenic site, and 2 other rmAbs showed reduced binding to
recHA with mutations in two (145-C09) or three (146-B09) anti-
genic sites (Fig. 2A and B).
Of the rmAb affected by mutations in single antigenic sites, 3
(145-D11, 146-C07 and 146-D11) were affected by the same two
point mutations (A139K and K142S) within antigenic site Ca2.
Binding of two other rmAbs (069-A09 and 139-22a) were reduced
by Sa antigenic site mutations, G155K and K160E. 139-22a showed
less reduction in binding with either mutation (Fig. 2A and B), and
consistent with this observation, we have previously shown that
139-22a binds to recHA with about 100 times higher afﬁnity than
does 069-A69 (Wilson et al., 2014). Reduced HA binding to rmAb
065-C05 was observed by a T72K substitution, which is within
antigenic site Cb.
Of the two rmAb affected by mutations in multiple antigenic
sites, 145-C09 binding is affected by residue changes in sites Ca2
and Sb, since mutations K142S and T184K independently reduce
binding. Similarly, mutations K160E (Sa), T184K (Sb), and R221E
(Ca2) all reduced binding by rmAb 146-B09 and indicated that the
binding footprint may span the monomer–monomer interface of
the HA trimer (Fig. 2B). Although antigenic sites are deﬁned as
functionally distinct (Caton et al., 1982), anti-HA antibodies that
span multiple sites (Matsuzaki et al., 2014; Tsibane et al., 2012) as
well as those that cross the monomer-monomer interface (Barbey-
Martin et al., 2002; Iba et al., 2014) have been described. Such
antibodies might not be identiﬁed when using a classical antigenic
mapping approach via mAb escape mutants, as a single mutation
would probably be sufﬁcient to avoid neutralization (Caton et al.,
1982; Matsuzaki et al., 2014).
Binding of the remaining rmAb, 065-D01, was not markedly
affected by any of the point mutations in the recHA panel; thus the
epitope for this rmAb could not be determined in this assay
(Fig. 2A). However, further analysis (see below) suggests that this
rmAb binds at least partly within the Sa antigenic site.
rmAb germline gene usage and CDR3 sequence indicate constraints
on the light chain
We previously sequenced and reported the germline gene
analysis data for these rmAb (Wilson et al., 2014). Two rmAb in
this panel (146-C07 and 146-D11) may be clonally related in that
they have the same IgH and IgL germline segments, but have
different somatic mutations. Both of these rmAb are equally affected
by the same two residue changes in antigenic site Ca2 (Table 3). A
third rmAb, 145-D11, employs a closely-related IgL V/J combination
and has a similar IgL CDR3 sequence as 146-C07 and 146-D11, but
has a different IgH V/D/J combination (Table 3), and this rmAb is
also affected by the same two residues. Similarly, 069-A09 and 139-
22a share identical IgL V/J genes and CDR3 sequence, but show
distinct IgH gene usage and CDR3 sequences, and are both speciﬁc
for the Sa antigenic site, further suggesting that the light chain may
be important in HA antigenic targeting. However, since this panel of
antibodies does not include a pair with closely-related heavy chain
VDJ and CDR3 and different light chain usage, further studies are
needed to determine if the light chain is particularly important in
determining the antibody’s antigenic target.
rmAb reactivity against drifted H1N1pdm09 viruses isolated from
humans
Based on the epitope proﬁle of the panel of rmAb, we selected a
group of eight H1N1pdm virus natural isolates that contained variant
residues likely to affect rmAb binding activity (Table 2). Ferret post-
infection antisera are typically used to antigenically characterize
inﬂuenza viruses and a reduction in HI titer of 8-fold or greater
relative to the homologous titer of the vaccine strain is generally
considered to be a signiﬁcant antigenic difference and may warrant
an update of the seasonal vaccine strain (Russell et al., 2008; Garten
et al., 2009). CA/07 ferret antisera, and pooled sera from the mice
used to prepare rmAb, had similar HI activity against CA/07 (vaccine
strain) and Ukr/2011, Nor/2009, Mass/2011, Ind/2012 and Penn/2010
(Table 4), indicating that these viruses are antigenically similar to CA/
07. HI titers against Ont/2012 were more than 8-fold lower than to
CA/07 using both mouse and ferret antisera; ferret antisera also had
8-fold reduced HI titer against Par/191 while mouse sera had 4-fold
reduced HI titers against Mex/2009 (Table 4). Ferret antisera MN
activity paralleled that of HI activity against this virus panel, with the
exception of a Z16-fold drop in MN titer against Mex/2009 and Ind/
2012 that did not correlate with the HI titer. Due to the limited
amount of mouse sera, MN could not be determined with mouse sera
for this panel of viruses.
We further tested ELISA, HI and MN activity of each of the 72
possible rmAb/virus combinations, relative to the rmAb activity
against CA/07 (Table 5 and Supplementary Table 1). ELISA binding
analysis revealed the rmAbs mainly bound as predicted (i.e. virus
containing a signiﬁcant amino acid change in the identiﬁed rmAb
antigenic binding site disrupted binding (Table 5)). Exceptions
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were 15 rmAb/virus that bound well despite apparently signiﬁcant
changes within the identiﬁed antigenic site (indicated by n in
Table 5). In addition, one rmAb/virus pair (146-B09 vs Penn/2010)
bound poorly despite the lack of an obvious change that would
reduce binding, while another rmAb/virus combination (065-C05
vs Mass/2011) failed to bind despite being identical to CA/07 in the
determined antigenic site. Interestingly, rmAb 145-C09, which in
BLI assays showed reduced binding to recHA mutated in either Ca2
or Sb, showed enhanced reactivity (48-fold higher titer) for Mass/
2011 despite the A141E change in Ca2.
HI activities against the H1pdm virus panel were generally
consistent with ELISA binding (Table 5). In every case where ELISA
binding was eliminated, no HI activity was seen, although in two
cases (145-C09 vs Ind/2012 and 146-B09 vs Penn/2010 (Table 5)) HI
activity was maintained in spite of reduced ELISA binding. However,
in some cases, ELISA activity was maintained while HI activity was
markedly decreased or lost (Table 5). Examples include the Sa-
targeting rmAb 069-A09 and 139-22a, which maintained ELISA
binding activity toward Nor/2009 but, as expected due to the K154E
change in this virus’s Sa antigenic site, fail to show HI activity; and
the Cb-speciﬁc rmAb, 065-C05, which lost most HI activity against
Ukr/2011 and Ont/2012, despite equal binding based on ELISA, and
in spite of the lack of mutation in antigenic site Cb of Ont/2012.
Although 6 of the viruses were antigenically identical to vaccine
virus as measured bymouse and/or ferret antisera in HI assays, all 8 of
the viruses showed reduced recognition by at least one rmAb. (It is
important to note that these viruses are not representative of the
global population of H1N1pdm09 viruses, since they were deliber-
ately chosen to have mutations in and around the recognition sites of
the rmAb). Seven of the 9 rmAb had no HI activity against Ont/2012
and an eighth showed a marked reduction in HI activity, leaving only
146-B09 capable of efﬁciently recognizing the virus in HI assays. This
virus, which contains multiple amino acid variations across the Ca2,
Sa and Sb antigenic sites, also demonstrated reduced HI titers both to
ferret antisera raised against CA/07 and to our mouse sera, and is
therefore expected to be less susceptible to immunity induced by the
H1N1pdm09 component of current TIV. Par/2011 also showed a 48-
fold reduction in HI titer with ferret antisera. However, this virus was
well recognized by the mouse serum from which rmAb were pre-
pared, and consistent with this, 8 of 9 rmAb recognized Par/2011 in HI
assays. In contrast, mouse sera HI activity was reduced 4-fold toward
Mex/2009, but 6 of 9 rmAb displayed HI activity toward this virus.
The three rmAb that lost ELISA and HI activity with this virus included
the Sa-speciﬁc as well as 065-D01, indicating that 065-D01 (which did
not have a binding footprint assigned to it based on the BLI analysis)
also binds at least partially within antigenic site Sa.
Virus neutralization (most commonly measured using MN
assays) and HI activity have been shown to correlate with protec-
tion against inﬂuenza virus infection (McCullers and Huber, 2012;
Reber and Katz, 2013). MN activity of rmAb mainly paralleled their
HI activity (Table 5), with several rmAb/virus combinations showing
ELISA binding while MN activity was undetectable, even though the
same rmAb did neutralize other viruses in the panel. This conﬁrms
that antibodies can bind to HA in known antigenic sites without
having virus-neutralizing activity and without showing HI activity.
For eight rmAb/isolate combinations (i.e. 145-C09 vs Par/2011 and
069-A09 vs Ukr/2011), MN activity was lost while HI activity was
still maintained, indicating that the MN assay may be more
sensitive to changes in binding afﬁnity than HI.
Cross-reactivity against historic H1N1 viruses
H1N1 viruses entered the human population in 1918, and the
swine population shortly afterward. This subtype therefore
includes a much wider range of sequence diversity than is
represented in the H1N1pdm09 lineage tested above. We pre-
viously showed that, while none of these rmAb reacted with the
recHA of A/Bris/59/07 in ELISA, three bound efﬁciently to recHA
of SC/18 and one further bound to IA/30 (Wilson et al., 2014). We
used the rmAb panel to perform HI assays on these two as well
as four other H1N1 viruses that span more than 90 years of
antigenic drift (1918, 1930, 1943, 1976, 1977, 1991 and 2009) and
include a range of variation within antigenic sites (Table 2). For
most of the virus/rmAb combinations, no HI activity was present
(Table 6). The two Sa-speciﬁc antibodies (069-A09 and 139-22a)
had HI activity against SC/18, as did 065-D01. 146-B09 had HI
activity against NJ/76, but required a roughly 15-fold increase in
antibody concentration opposed to CA/07. Although 065-D01
bound IA/30 at low concentration in our ELISA assay, HI activity
was not observed, similar to the discordance between ELISA and
HI noted above. rmAb 065-D01 showed the same ELISA and HI
pattern as rmAb 069-A09 and 139-22a against both H1N1pdm09
panel and historical viruses, further suggesting that 065-D01
also targets antigenic site Sa but that its precise footprint is not
covered by the mutations in the HA panel used for epitope
mapping.
Discussion
Inﬂuenza infection or vaccination typically induces a protective,
strain-speciﬁc, antibody response mainly directed against the HA
glycoprotein. Current serological assays used to determine corre-
lates of protection against inﬂuenza virus infection, including HI
and MN assays, quantify the antibody response but are relatively
crude measures of overall antibody reactivity. The advances in
next-generation sequencing technology raise the possibility of
using sequence-based repertoire analysis to rapidly assess the
antibody response to inﬂuenza vaccination or infection. For this
approach to be useful, antibody variable region sequence signa-
tures must be correlated to their functional capabilities.
We have previously demonstrated that the murine immune
response to HA of H1N1pdm09 is relatively restricted, originating
from roughly 100 heavy V/D/J and 35 light chain V/J germ-line
combinations (Wilson et al., 2014). Here we determined the partial
binding footprints of a subset of high-afﬁnity rmAb cloned from
this response to identify the antigenic site(s) they recognize. Even
within this small subset of high-afﬁnity antibodies, at least seven
unique binding footprints were present, targeting all four anti-
genic sites of HA1. Consistent with the lack of a detectable cross-
reactive response in the immunized mice, no stem-reactive anti-
bodies were identiﬁed. Humans infected with H1N1pdm09 have
been shown to have detectable but rare cross-reactive antibodies;
however, most of these are probably related to expansion of
memory B cells originally raised against distantly-related H1N1
viruses (Wrammert et al., 2011).
This diversity in antigenic site recognition contrasts with pre-
vious observations that BALB/c and CBA/Ca mice immunized with
H3N2 inﬂuenza virus (Patera et al., 1995) mainly target a single
antigenic site, and that mice vaccinated against H1N1pdm09 mainly
produced antibodies directed against two antigenic sites (Sa and Sb)
(Rudneva et al., 2012). However, H1N1pdm09 (Matsuzaki et al.,
2014) and PR/8 (Staudt and Gerhard 1983) infection or recHA from
CA/04 immunization (Chen et al., 2013) generated a more diverse
response that targeted multiple antigenic sites, similar to our
ﬁndings. Although there could be an intrinsic difference in immu-
nodominance between the viruses used, it is more likely that the
difference between these studies is due to the immunization
schedule used as well as timing of the B cell analysis.
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Two of the cloned rmAb (146-D11 and 146-C07) are composed of
the same IgH and IgL gene segments but encode different somatic
mutations (Table 3). Unsurprisingly, both of these rmAbs showed
identical patterns of binding to antigenic site Ca2 in our epitope
mapping and virus panel screen, although with different afﬁnities
(Wilson et al., 2014). Interestingly, 145-D11, whose binding is also
affected by the same residue changes in the Ca2 antigenic site,
contains a similar IgL VJ rearrangement and CDR3 sequence but is
combined with a different IgH rearrangement (Table 3). Similarly,
rmAb 069-A09 and 139-22a share an IgL VJ rearrangement and CDR3
sequence but have different IgH VDJ rearrangements, and have an
overlapping binding footprint within the Sa antigenic site (Table 3).
Further, a pair of human derived anti-stemmAb that compete for the
same HA-stem also share IgL VJ genes but use a completely different
IgH VDJ rearrangement has previously been reported (Hu et al.,
2013). These observations suggest that the rearrangement pattern of
the light chain alone may be useful in predicting antigenic site
targeting, consistent with the more limited IgL germ-line usage
compared to IgH (Wilson et al., 2014). However, further examples
are needed to test this possibility.
Recently, epitope mapping of H1N1pdm09 HA revealed that it
is antigenically similar to PR/8, but may have a novel epitope
(Matsuzaki et al., 2014). Although our study, and those of others
(Rudneva et al., 2012; Chen et al., 2013; Retamal et al., 2014), did
not observe this epitope, this highlights the need to further
expand our understanding of the antigenicity of H1N1pdm09
HA, beyond that of the classical antigenic mapping of the HA of
PR/8 (Caton et al., 1982). This will not only aid our understanding
of the protective antibody response against this virus, but will also
support surveillance and vaccine candidate selection efforts that
monitor viral drift in the human population.
Inﬂuenza viruses typically undergo antigenic drift over time due
to host immune pressure, during which time one or more antigenic
sites on the HA mutate until an immune response against prior
viruses is no longer completely protective. Although single amino
acid mutations are capable of causing marked antigenic change
(Koel et al., 2013, 2015), antigenic drift is usually associated with
mutations in several amino acids located in more than one
antigenic site. We examined the effect of a limited number of
amino acid changes on functional recognition both by reference
ferret antisera and our panel of rmAb, making use of natural isolates
of H1N1pdm09. Although in most cases these natural isolates
showed no evidence of antigenic drift when evaluated by HI using
reference ferret serum, rmAb that were speciﬁc for individual
antigenic sites lost HI ability against each of the viruses. Thus,
cryptic antigenic variation can arise in a viral population, in the
form of viruses are not recognized by subsets of the antibodies. It is
possible that such viruses may act as intermediates for variants
with changes in multiple antigenic sites that are capable of escaping
immunity induced by the current vaccine strain.
Although in most cases rmAb activity could be predicted from
knowledge of the sequence of HA and the antigenic targeting of the
rmAb (75% of rmAb/virus combinations), a signiﬁcant number of
antibodies retained binding activity in spite of signiﬁcant amino acid
changes in the respective HA antigenic binding site. In some cases, HI
and MN activity was reduced in spite of rmAb binding, suggesting that
the reduced afﬁnity associated with the sequence changes reduced
functional activity of the antibody, but in other cases normal HI and
MN levels were retained. Since the virus isolates were chosen based
on having biologically signiﬁcant amino acid changes (e.g. Lys to Asp;
Leu to Pro), these antibodies show some tolerance in their binding
ability. Conversely, in two of the 72 combinations, rmAbs failed to bind
despite a lack of change in the putative binding site, suggesting that
either the binding footprint was incompletely mapped for these
rmAbs, or that amino acid variation outside the antigenic site may
alter antibody recognition, e.g. by altering the conformation of the
antigenic site. Finally, in one case, an Ala to Glu change in the antigenic
site was associated with an increase in binding.
In spite of these exceptions, identifying the antigenic site
(s) targeted by each rmAb generally allowed us to accurately
predict binding and HI reactivity toward historic H1N1 and
H1N1pdm09 variant viruses, based on their HA sequence. H1 HA
has undergone antigenic drift in humans and, to a lesser extent, in
swine, since about 1918, when the 1918 pandemic A(H1N1)
entered the human and swine populations. When comparing HI
activity pattern against HA from historical H1N1 viruses circulat-
ing from 1918 to 2007, only 4 rmAb showed functional activity,
with the most cross-reactivity seen with Sa-reactive rmAb against
viruses with a relatively conserved Sa site. However, in other cases
viruses with relatively minor or no changes in the antigenic site
predicted to be involved in binding showed no HI activity. Again,
this may be due to the binding footprint for the rmAb being
incompletely mapped, or due to conﬁrmation changes caused by
amino acid variation outside an antigenic site.
Cross-reactivity is not all or nothing. Single site mutations can
alter antibody function (ie. HI and MN activity) while still
permitting antibody binding as determined by ELISA, as demon-
strated by several virus/rmAb combinations that showed discor-
dance between ELISA, HI, and MN activity. In most of these
situations, epitope mapping predicted reduced antibody binding,
and HI and/or MN activity was lost, but ELISA reactivity was
retained. Similarly, H1N1pdm escape mutants selected in the
Table 1
Viruses and recombinant proteins used in this study.
Inﬂuenza A virus Abbreviation Subtype GISAID accession Identity of HA to CA/07 (HA1)
A/California/07/2009 CA/07 A(H1N1)pdm09 EPI177294 –
A/South Carolina/1/1918 SC/18 A(H1N1) EPI5571 86% (82%)
A/swine/Iowa/15/1930 IA/30 A(H1N1) EPI124024 87% (83%)
A/AA/Marton/1943 Mar/43 A(H1N1) EPI240837 82% (75%)
A/New Jersey/1976 NJ/76 A(H1N1) EPI241033 91% (88%)
A/USSR/90/1977 USSR/77 A(H1N1) EPI390455 80% (72%)
A/Texas/ 36/1991 Tex/91 A(H1N1) EPI159432 79% (71%)
A/Mexico/5569/2009 Mex/2009 A(H1N1)pdm09 EPI273882 99% (98%)
A/Norway/3206/2009 Nor/2009 A(H1N1)pdm09 EPI240393 99% (98%)
A/Ukraine/130/2011 Ukr/2011 A(H1N1)pdm09 EPI320158 98% (97%)
A/Pennsylvania/07/2010 Penn/2010 A(H1N1)pdm09 EPI280320 98% (97%)
A/India/2005/2012 Ind/2012 A(H1N1)pdm09 EPI422601 98% (97%)
A/Massachusetts/06/2011 Mass/2011 A(H1N1)pdm09 EPI310002 98% (97%)
A/Paraguay/191/2011 Par/2011 A(H1N1)pdm09 EPI349352 97% (97%)
A/Ontario/RV117/2012 Ont/2012 A(H1N1)pdm09 EPI357951 97% (96%)
The viruses and/or recombinant proteins used in this study are listed. The abbreviations by which they are referred in the text and the identity of the virus HA and HA1
domain to A/California/07/2009 is shown.
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Table 2
Amino acid sequence of antigenic sites for historic H1N1 and H1N1pdm natural isolate viruses.
Cb Sa Ca2 Sa
70 71 72 73 74 75 124 125 137 138 139 140 141 142 153 154 155 156 157 159 160 161 162 163 164
CA/07 L S T A S S P N P H A G A K K K G N S P K L S K S
SC/18 . L . . . . . . S Y . . . S . . . S . . . . . . .
IA/30 . L . V . . . . . Y . . . S . . E . . . . . . . .
Mar/43 . L S E R - . K S . . . K S E . D G . . N . N N .
NJ/76 . L . V . . . . . Y . . . N E . . . . . . . . . .
USSR/77 . F S K K . . K S . K . K S E . N G . . N . . . .
Tex/91 L F S K E . . . S . N . K S - . N G L . N V . . .
Bris/59 . I S K E . . . S . N . E S G . N G L . N . . . .
Par/2011 P . . . . . . . . . . . . . . . . D . . . . . . .
Mex/2009 . . . . . . . . . . . . . . . . . . . . . . . E .
Ind/2012 . . . . . . . . . . D . . . . . . . . . . . . . .
Nor/2009 . . . . . . . . S . . . . . . E . . . . . . . . .
Ukr/2011 . . . . R . . . . . . . . . . . . . . . . I/L . . .
Penn/2010 . . . . . . . . T . . . . . . . . . . . . . N . .
Mass/2011 . . . . . . . . . . . . E . . . . . . . . . N . .
Ont/2012 . . . . . . . . . . . . . R . . E . . . . . . . .
Ca1 Sb Ca1 Ca2 Ca1
166 167 168 169 170 184 185 186 187 188 189 190 191 192 193 194 195 203 204 205 221 222 235 236 237
CA/07 I N D K G T S A D Q Q S L Y Q N A S S R R D E P G
SC/18 V . N . . . G T . . . . . . . . . . . K . . . . .
IA/30 V . N . . . . T . . . . . . . . . . . K . G . . .
Mar/43 V . K . . N I K . . . T . . . K E . . N . G K . .
NJ/76 V . N . . . . T . . . . . . . . . . . K . G . . .
USSR/77 V . N . E N I E . . K T I . R K E . . N . G . . .
Tex/91 V . N K E N I G . . R A I . H T E . . H . . . . .
Bris/59 A . N . E N I G . . K A . . H T E . . H . . . . .
Par/2011 . . . . . . T . G . . . . . . . . T . . . . . . .
Mex/2009 . . . . . . . . . . . . . . . . . T . . . . . . .
Ind/2012 . . . . . . T . . . . . I . . . . T . . . . . . .
Nor/2009 . . . . . . . . . . . . . . . . . T . . . . . . .
Ukr/2011 . . . . . N/T T . . . . . . . . . . T . . . . . . .
Penn/2010 . . . . . . . T . . . . . . . . . T . . . . . . .
Mass/2011 . . . . . . . T . . . . . . . . . T . . . G . . .
Ont/2012 . . . . . . T . . . . R . . . . . T . . . . G . . .
Antigenic sites are based on those determined for A/PR/8/34 by Caton et al. (1982) (Reference (Caton et al., 1982)).
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Table 3
rmAb germline gene usage and respective amino acid changes that affect CA/07 HA binding as identiﬁed by epitope mapping.
rmAb IgH V/D/J CDR3 IgL V/J CDR3 T72K A139K K142S G155K K160E D168K T184K R221E
065-
C05
1–53n01/2-2n01/
4n01
CARYGYDEDAMDYW 4–59n01/
1n01
CQQWSNNPPTWTF
065-
D01
1–82n01/2–4n01/
1n01
CARDWDYYFDVW 14–111n01/
5n01
CLQHDEFPLTF
069-
A09
1–50n01/2–10n02/
2n01
CARRDSILDCW 14–130n01/
5n01
CLQFYEFPLTF
139-
22a
1–69n01/2–5n01/
3n01
CAKGGDYSNSFAFW 14–130n01/
5n01
CLQFYEFPLTF
145-
C09
5-4n01/1-1n01/
2n01
CARGGITTVVEDLDYW 3-2n01/5n01 CQQSKEVPLTF
146-
B09
1–80n01/1-1n01/
4n01
CARTNYYGSNYPLYSMDYW 6–23n01/
5n01
CQQYTTLYTF
145-
D11
1–82n01/2–4n01/
2n01
CAYDYDYYFDYW 4–57n01/
3n01
CQQRSSYPLTF
146-
C07
14-4n01/3-2n02/
3n01
CTSGGSSGYGGAYW 4–59n01/
2n01
CQQWSSNPPTF
146-
D11
14-4n01/3-2n02/
3n01
CTTGGSSGYGGAYW 4–59n01/
2n01
CQQWSTNPPTF
Germline gene usage was determined in previous work (Wilson et al., 2014; Reference (Wilson et al., 2014). Antigenic site Sa is shown in red, Ca1/2 in yellow, Sb in cyan, and Cb in blue.
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presence of mAbs can show reduced HI activity even though
antibodies can still bind in ELISA (Rudneva et al., 2012; Chen et
al., 2013; Kaverin et al., 2004). In these cases, presumably the HA
variant reduces rmAb binding afﬁnity (or perhaps increases the
receptor-binding afﬁnity for sialic acids (Clarke et al., 1985; Laeeq
et al., 1997; Temoltzin-Palacios and Thomas, 1994; Yewdell et al.,
1986)) so that the antibody is no longer able to effectively
compete with sialic acid binding, while ELISA, in the absence of
competitors for binding, binding was still easily measured.
Studies are underway to determine if such rmAb/virus interac-
tions, while losing the ability to directly neutralize virus in vitro,
still maintain protective effector functions in vivo (for example,
via interactions with complement and antibody-dependent cell-
mediated cytotoxicity (ADCC)). In any case, memory B cells
expressing antibodies which still bind to antigenic variants are
potential substrates for somatic hypermutation, and these (rather
than naïve B cells) may be the foundation for protective anti-
bodies against drifted variants of virus.
Characterization of infection and/or vaccine induced B cell
response(s) at the monoclonal level will allow assessment of the
respective protective and non-protective components of the
immune response. Understanding the components of the response,
and the diversity of epitopes targeted that neutralize virus, will
further our understanding of vaccine efﬁciency. In turn, under-
standing the molecular nature of the neutralizing antibody/antigen
interactions can aide in surveillance efforts to more quickly identify
mutations, as viruses evolve in nature, that may have an impact on
existing human herd immunity but which may escape identiﬁcation
with post-immunization reference ferret antisera.
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Materials and methods
Viruses and cells
The viruses and recombinant HA (recHA) used in these experi-
ments are summarized in Table 1, and the amino acid sequence of
the virus’s antigenic sites are listed in Table 2. Virus isolate stocks
were grown in 10 day old embryonated chicken eggs for 48 h at
37 1C. The sequences of all virus HA’s were conﬁrmed before use.
Recombinant monoclonal antibodies (rmAb)
Single-cell cloning of the rmAb used in these experiments was
described previously (Wilson et al., 2014). Brieﬂy, naïve C57BL/6
mice (Jackson) were immunized by infection with H1N1pdm virus
(OH/07(H1N1pdm), antigenically identical to CA/07(H1N1pdm)),
followed 21 days later by a boost with 2011/12 commercial
seasonal trivalent inactivated vaccine (TIV) (Fluarix), containing
HA and NA from CA/07(H1N1pdm), VIC/210(H3N2) and B/BR/60.
Three days later, spleens were harvested and B cells reactive with
H1N1pdm recHA were sorted onto glass slides by ﬂow cytometry.
IgH VDJ and IgL VJ gene segments were ampliﬁed and subcloned
into plasmid vectors which provided human constant regions for
heavy or light chain respectively, as well as a signal sequence and
promoter sequences for expression in mammalian cells as pre-
viously described (Wilson et al., 2014). 293T cells were transiently
transfected with single cell matching pairs of IgH and IgL expres-
sing vectors, and supernatant was collected and concentrated to
25 mg rmAb/ml working stocks.
The nine rmAb used in these experiments are listed in Table 3;
the germline gene usage and CDR3 sequences for these rmAb have
been previously published (Wilson et al., 2014).
Recombinant HA cloning and transient expression
A codon-optimized cDNA encoding the ectodomain (residues
1-501) of the mature HA gene of A(H1N1) pdm09 virus CA/07 was
D14NI372K
S121
E115K
T72K
G155KK160EG155K
S289K
N129D
D127K
G53K
R45G K36E
A139K
K142S
R221E
D168K
T184K
D274K
P271K
Fig. 1. Epitope mapping using a recHA point mutation panel. A panel of 20 respective single point mutations in recHA was constructed. (A) Sequence changes are shown;
(B) Their locations are indicated on the 3D structure of HA.
J.R. Wilson et al. / Virology 485 (2015) 252–262258
sub-cloned into a pIEx-4 vector (EMD Millipore, MA) using the In-
Fusion HD cloning system (Clontech, CA). HA mutants containing
point mutations within or near known antigenic sites were gener-
ated from this wild-type pIEx-4-HA clone using the QuickChange
Lightning Site-Directed Mutagenesis Kit (Agilent, CA) (Fig. 1). The
point mutations were designed to induce signiﬁcant size and/or
charge change in surface-accessible residues. One mutation, S289K,
removed a putative glycosylation addition site. All recombinant HA
(recHA) proteins contained a thrombin cleavage site at the
C-terminus followed by a trimerizing sequence (foldon) from the
Fig. 2. Epitope map of rmAb as determined by Biolayer Interferometry (BLI). (A) rmAb binding afﬁnity to each mutant HA and the percent response compared to wild-
type CA/07 HA was determined. A greater than 50% reduction in binding activity was the cutoff for signiﬁcance. (B) Epitopes whose mutations lead to a signiﬁcant reduction
in rmAb binding are indicated on the 3D structure of CA/07 HA.
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bacteriophage T4 ﬁbritin for generating functional trimers (Yang
et al., 2010), and a His-Tag to aid with subsequent assays and
detection. Constructs were transiently transfected into suspension
Sf9 cells (EMD Millipore, MA) using the Cellfectin II transfection
reagent (Life Technologies, NY), following manufacturer’s protocols.
Transfected cells were transferred into 125 ml conical ﬂasks and
maintained at 27 1C for ﬁve days in an orbital shaker/incubator (at
170 rpm). The recHAs secreted in the culture supernatant were
assessed for expression by Western blot using anti-His antibody
(Qiagen, CA), and applied to epitope mapping analysis without
further puriﬁcation.
Biolayer interferometry (BLI) assay
Binding to recHA by the cloned antibodies was measured using
BLI on an Octet Red 96 instrument (Pall ForteBio, CA) according to
the manufacturer’s instructions. Brieﬂy, antibodies were diluted to
10 mg/ml in kinetics buffer (PBS containing 0.02% (v/v) Tween-20,
0.005% (v/v) sodium azide, and 100 mg/ml bovine serum albumin).
recHA was coupled to anti-penta-His biosensors and antibody
binding data were collected and analyzed using the system soft-
ware and ﬁtted to a 1:1 binding model. An HA1-speciﬁc mAb (26-
D11; Immune Technology Corp., New York) and an HA2-speciﬁc
mAb, Y2_50132_1C04 (provided by Patrick Wilson, University of
Chicago), whose binding locations on the H1pdm HA were
previously determined (Wrammert et al., 2011), were included in
the assay as controls. Data are presented as percentages of anti-
body binding to mutants compared to binding to WT CA/07
(100%). A reduction of Z50% in binding response for each mutant
compared to the wild type recHA was considered signiﬁcant
(Throsby et al., 2008).
Hemagglutination inhibition assays
rmAbs were screened for neutralizing activity against a panel of
natural H1N1pdm isolates by the hemagglutination inhibition (HI)
assay as previously described (World Health Organization, 2011).
Brieﬂy two-fold serial dilutions of post immunization ferret anti-
sera or mouse sera and three-fold serial dilutions of rmAb were
mixed with equal volume of standardized inﬂuenza viruses (4 HA
U/25 ml/well) for 15 min interaction. Standardized (0.5%) turkey
red blood cells (50 ml) were added. After 30 min incubation at
room temperature, HI titers were recorded as highest dilution of
antiserum that completely inhibits hemagglutination.
ELISA assays
For detection of HA cross-reactivity, ELISA assays were per-
formed as previously described (Wilson et al., 2014). Brieﬂy, Costar
Hi Bind plates (Corning Inc., Tewksbury, MA) were coated overnight
with the appropriate virus isolate (25 HA units/well) at 4 1C. Plates
were blocked for 1 h with PBS/0.1% Tween-20 (PBST) containing
1.5% BSA (blocking buffer) at room temperature. All rmAbs were
serially titrated three-fold in blocking buffer and allowed to
incubate with antigen-coated plates for 1 h at room temperature.
After three PBST washes, wells were probed with goat anti-human
(H&L)–HRP (Thermo Scientiﬁc) for 1 h at room temperature. Plates
were washed three times with PBST and signal was developed with
1 step™ Turbo TMB-ELISA reagent (Thermo Scientiﬁc). Reactions
were stopped with 1 N sulfuric acid and absorbance was read at
450 nm.
26-D11
Sa; S121K
Y2_50132_1C04
I372K
065-C05
Cb; T72K
139-22a
Sa; G155K
069-A09
Sa; G155K/K160E
145-C09
Sb/Ca2; T184K/K142S
145-D11
146-C07
146-D11
Ca2; A139K/K142S 
146-B09
Sa/Sb/Ca2; K160E/T184K/R221E
Binding of mAb 065-D01 was not affected by any mutation 
Fig. 2. (continued)
Table 4
Antisera HI and MN activity toward H1N1pdm human isolates.
CA/07 Ukr/2011 Mex/2009 Nor/2009 Ont/2012 Mass/2011 Ind/2012 Par/2011 Penn/2010
þAntisera HI MN HI MN HI MN HI MN HI MN HI MN HI MN HI MN HI MN
Ferret 256 512 512 128 256 32 128 128 4 o4 512 1024 512 o32 32 32 256 128
Mouse 160 NT 160 NT 40 NT 160 NT o20 NT 320 NT 160 NT 160 NT 160 NT
Data are reported as sera endpoint titer required to inhibit 4 HA units of respective virus. Day 3 post-boost sera was pooled from 5 mice and used for HI assays. Data are
representative of one experiment repeated three times.
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Table 5
ELISA, HI, and MN activity of rmAb’s toward natural H1N1pdm human isolates relative to A/California/07/2009. Endpoint titers were determined by ELISA, HI and MN assays and their fold change from CA/07 was determined.
Data is representative of the average of 3–4 assays. “¼” indicates titer similar to CA/07, “↑” indicates 48 fold increase from CA/07, “↓” indicates 48 fold decrease from CA/07, and “0” indicates no ELISA, HI, or MN activity observed
at 12500, 12500, or 3125 ng/ml, respectively.
Table 6
HI activity of rmAb toward historic H1N1 viruses.
CA/07 Tex/91 USSR/77 NJ/76 Mar/43 IA/30 SC/18
065-C05 1625 – – – – – –
065-D01 98 – – – – – 98
069-A09 200 – – – – – 3125
139-22a 200 – – – – – 98
145-C09 3125 – – – – – –
145-D11 200 – – – – – –
146-B09 98 – – 1390 – – –
146-C07 200 – – – – – –
146-D11 200 – – – – – –
Data are reported as ng/ml required to inhibit 4 HA units of respective virus. Data are representative of one experiment repeated three times. “–” indicates titer 412500 ng/ml.
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Microneutralization assay
MN assays were performed as described (World Health
Organization, 2011). The minimum detection limit of this assay
was a titer of 20 for post immunization ferret antisera.
Appendix A. Supporting information
Supplementary data associated with this article can be found in
the online version at http://dx.doi.org/10.1016/j.virol.2015.08.004.
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